Conditions: Lower Respiratory Tract Infection
Keywords: Infection; Meropenem; Pharmacokinetics; Pharmacodynamics
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 79
Healthy volunteers: no

Brief summary:
To evaluate the clinical and economical benefits of a meropenem dosage strategy based on a population pharmacokinetic(PPK)-pharmacodynamic(PD) model in lower respiratory tract infection patients.

Detailed description:
* Subjects:lower respiratory tract infection patients
* Study design:randomized control study.The patients in study group will accept meropenem therapy with the regimen decided by a software developed from a PPK-PD model. The patients in control group will accept meropenem therapy with the regimen decided by attending physician.
* Primary endpoint: clinical successful rate of meropenem therapy. The clinical efficiency of meropenem therapy will be evaluated one week later from stop of meropenem therapy.
* Second endpoint: amount of used antibiotics and bacteriological successful rate.

Arms:
arm 1: The participants in control group will accept routine meropenem therapy arm 2: The participants in study group will accept meropenem therapy based on a PPK and PD model.

Interventions: intervention 1: Routine meropenem therapy intervention 2: Meropenem therapy based on a PPK and PD model
Intervention descriptions: intervention 1: Participants in control group will accept meropenem therapy with regimen routinely decided by attending physician intervention 2: Participants in study group will accept meropenem therapy based on a software developed from a PPK and PD model

Protocol document: